Journal of Neuro-Oncology

, Volume 140, Issue 3, pp 669–677 | Cite as

Prognosis and treatment outcomes of central neurocytomas: clinical interrogation based on a single center experience

  • Joonho Byun
  • Seok Ho HongEmail author
  • Min Jae Yoon
  • Sae Min Kwon
  • Young Hyun Cho
  • Jeong Hoon Kim
  • Chang Jin Kim
Clinical Study



Central neurocytoma (CN) is a very rare neuronal neoplasm. The clinical implications of the potential prognostic factors for these lesions, including tumor atypia, have therefore not been clarified.


Forty CN patients were enrolled and reclassified as typical or atypical in accordance with an MIB-1 labeling index (LI) of above and below 2%.


We classified our retrospective study cohort as 21 (52.5%) typical and 19 (47.5%) atypical CN cases. No significant differences were found in terms of sex, mean age, mean tumor size or tumor location between these groups. Recurrences occurred in 2 (9.5%) typical and 6 (33.3%) atypical cases. The typical CN 2-,3- and 5-year PFS rates were 100%, 100%, 92.3%, and those for the atypical group were 93.8%, 78.1%, 65.1%, respectively (p = 0.02). The PFS rates did not statistically differ by treatment modality (gross total resection alone, subtotal resection (STR) alone and STR plus radiation therapy (RT) or radiosurgery (RS)) either in the whole cohort (p = 0.75) or in the typical CN and atypical CN subgroups (p = 0.45 and 0.98, respectively). An atypical histology was the only prognostic indicator of recurrence by univariate analysis (hazard ratio: 5.40, p = 0.04).


An atypical lesion (MIB-LI > 2%) is an important prognostic indicator in CN. The clinical implications of the extent of resection for CN patients are still debatable. The use of STR plus RT or RS may be a viable treatment strategy for CN but different therapeutic and follow-up approaches for atypical CN will be needed.


Central neurocytoma Atypical Prognosis Treatment 



We thank the referring physicians, our institutional neuroradiologists and pathologists.

Compliance with ethical standards

Conflict of interest

The authors declare no competing interests in relation to this study.


  1. 1.
    Hassoun J, Gambarelli D, Grisoli F, Pellet W, Salamon G, Pellissier JF, Toga M (1982) Central neurocytoma: an electron-microscopic study of two cases. Acta Neuropathol 56:151–156CrossRefGoogle Scholar
  2. 2.
    Hassoun J, Söylemezoglu F, Gambarelli D, Figarella-Branger D, Ammon Kv, Kleihues P (1993) Central neurocytoma: a synopsis of clinical and histological features. Brain Pathol 3:297–306CrossRefGoogle Scholar
  3. 3.
    Wang M, Zhou P, Zhang S, Liu X, Lv L, Wang Z, Ye F, Wang X, Jiang S (2018) Clinical feuatures, treatment, and long-term outcomes of central neurocytoma: a 20-year experience at a single center. World Neurosurg 109:259–266Google Scholar
  4. 4.
    Mackenzie IRA (1999) Central neurocytoma histologic atypia, proliferation potential, and clinical outcome. Cancer 85:1606–1610CrossRefGoogle Scholar
  5. 5.
    Schmidt MH, Gottfried ON, von Koch CS, Chang SM, McDermott MW (2004) Central neurocytoma: a review. J Neuro-Oncol 66:377–384CrossRefGoogle Scholar
  6. 6.
    Soylemezoglu F, Scheithauer BW, Esteve J, Kleihues P (1997) Atypical central neurocytoma. J Neuropathol Exp Neurol 56:551–556CrossRefGoogle Scholar
  7. 7.
    Yasargil MG, Ammo KV, Deimling AV, Vanis AVA, Wichmann W, Wiestler OD (1992) Central neurocytoma: histopathological variants and therapeutic approaches. J Neurosurg 76:32–37CrossRefGoogle Scholar
  8. 8.
    Dutta SW, Kaleem TA, Muller DA, Peterson J, Harrell AC, Quinones-Hinojosa A, Trifiletti DM (2018) Central neurocytoma: clinical characteristics, patterns of care, and survival. J Clin Neurosci 53:106–111CrossRefGoogle Scholar
  9. 9.
    Ahmad Z, Din NU, Memon A, Tariq MU, Idrees R, Hasan S (2016) Central, extraventricular and atypical neurocytomas: a clinicopathologic study of 35 cases from Pakistan plus a detailed review of the published literature. Asian Pac J Cancer Prev 17:1565–1570CrossRefGoogle Scholar
  10. 10.
    Rades D, Schild SE, Fehlauer F (2004) Prognostic value of the MIB-1 labeling index for central neurocytomas. Neurology 62:987–989CrossRefGoogle Scholar
  11. 11.
    Imber BS, Braunstein SE, Wu FY, Nabavizadeh N, Boehling N, Weinberg VK, Tihan T, Barnes M, Mueller S, Butowski NA, Clarke JL, Chang SM, McDermott MM, Prados MD, Berger MS, Haas-Kogan DA (2016) Clinical outcome and prognostic factors for central neurocytoma: twenty year institutional experience. J Neuro-Oncol 126:193–200CrossRefGoogle Scholar
  12. 12.
    Hallock A, Hamilton B, Ang LC, Tay KY, Meygesi JF, Fisher BJ, Watling CJ, Macdonald DR, Bauman GS (2011) Neurocytomas: long-term experience of a single institution. Neuro-Oncology 13:943–949CrossRefGoogle Scholar
  13. 13.
    Rades D, Schild SE (2006) Treatment recommendations for the various subgroups of neurocytomas. J Neuro-Oncol 77:305–309CrossRefGoogle Scholar
  14. 14.
    Vasiljevic A, Francois P, Loundou A, Fe`vre-Montange M, Jouvet A, Roche P-H, Figarella-Branger D (2012) Prognostic factors in central neurocytomas: a multicenter study of 71 cases. Am J Surg Pathol 36:220–227CrossRefGoogle Scholar
  15. 15.
    Leenstra JL, Rodriguez FJ, Frechette CM, Giannini C, Stafford SL, Pollock BE, Schild SE, Scheithauer BW, Jenkins RB, Buckner JC, Brown PD (2007) Central neurocytoma: management recommendations based on a 35-year experience. Int J Radiat Oncol Biol Phys 67:1145–1154CrossRefGoogle Scholar
  16. 16.
    Garcia RM, Ivan ME, Oh T, Baranic I, Parsa AT (2014) Intraventricular neurocytomas: a systematic review of stereotactic radiosurgery and fractionated conventional radiotherapy for residual or recurrent tumors. Clin Neurol Neurosurg 117:55–64CrossRefGoogle Scholar
  17. 17.
    Anderson R, Ghatan S, Feldstein N (2003) Surgical approaches to tumors of the lateral ventricle. Neurosurg Clin N Am 14:509–525CrossRefGoogle Scholar
  18. 18.
    Milligan BD, Meyer FB (2010) Morbidity of transcallosal and transcortical approaches to lesions in and around the lateral and third ventricles: a single-institution experience. Neurosurgery 67:1483–1496CrossRefGoogle Scholar
  19. 19.
    Park ES, Cho YH, Kim JH, Kim SJ, Khang SK, Kim CJ (2012) Frontal transcortical approach in 12 central neurocytomas. Acta Neurochir 154:1961–1971CrossRefGoogle Scholar
  20. 20.
    Chen Y-D, Li W-B, Feng J, Qiu X-G (2014) Long-term outcomes of adjuvant radiotherapy after surgical resection of central neurocytoma. Radiat Oncol 9:242CrossRefGoogle Scholar
  21. 21.
    Paek SH, Han J-H, Kim JW, Park C-K, Jung H-W, Park S-H, Kim IH, Kim DG (2008) Long-term outcome of conventional radiation therapy for central neurocytoma. J Neuro-Oncol 90:25–30CrossRefGoogle Scholar
  22. 22.
    Karlsson B, Guo W-Y, Kejia T, Dinesh N, Pan DH-C, Jokura H, Kawagishi J, Eck ATCJv, Horstmann GA, Yeo TT, Yamamoto M (2012) Gamma Knife surgery for central neurocytomas. J Neurosurg 117:96–101CrossRefGoogle Scholar
  23. 23.
    Bui TT, Lagman C, Chung LK, Tenn S, Lee P, Chin RK, Kaprealian T, Yang I (2017) Systematic analysis of clinical outcomes following stereotactic radiosurgery for central neurocytoma. Brain Tumor Res Treat 5:10–11CrossRefGoogle Scholar
  24. 24.
    Kim JW, Kim DG, Chung H-T, Choi SH, Han JH, Park C-K, Kim C-Y, Paek SH, Jung H-W (2013) Radiosurgery for central neurocytoma: long-term outcome and failure pattern. J Neuro-Oncol 115:505–511CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Neurological Surgery, Asan Medical CenterUniversity of Ulsan College of MedicineSeoulSouth Korea
  2. 2.Department of Radiology, Konyang University HospitalUniversity of Konyang College of MedicineDaejeonSouth Korea

Personalised recommendations